Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation

Clinical trials for Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation explained in plain language.

Never miss a new study

Get alerted when new Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation trials appear

Sign up with your email to follow new studies for Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New hope for leukemia patients who Can't handle strong chemo

Disease control Completed

This phase 3 study tested a new drug, gilteritinib, combined with azacitidine for people with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The participants were adults who could not receive standard intensive chemotherapy. The study compared the combi…

Matched conditions: ACUTE MYELOID LEUKEMIA WITH FMS-LIKE TYROSINE KINASE (FLT3) MUTATION

Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation

Get alerted when new Acute myeloid leukemia with FMS-like tyrosine kinase (FLT3) mutation trials appear

New hope for leukemia patients who Can't handle strong chemo